Rhinosinusitis

Chronic rhinosinusitis (CRS) is a chronic sinus disease that affects between 5% and 12% of the general population.1–3 Despite substantially impacting the patient’s quality of life, it often remains underdiagnosed and undertreated.1 The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) recently published a CRS pocket guide providing a simplified clinical care […]

Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]

touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]

touchRESPIRATORY were delighted to catch up with Prof Peter Hellings (Catholic University of Leuven; University Hospitals of Leuven, Leuven, Belgium) to discuss this year’s EUFOREA global CRSwNP awareness day that took place on 20 April 2022 and the importance of physician and patient awareness for improved patient outcomes. Questions Can you highlight the burden of […]

Watch ENT specialists discuss key considerations in optimizing the management of patients with CRSwNP.

Aspirin-exacerbated respiratory disease (AERD) is a clinical triad of asthma, nasal polyposis and sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). These patients have severe sinopulmonary inflammation, often refractory to standard treatments.1 However, significant advances in the management of both asthma and nasal polyposis allow for new treatment options and management algorithms. This article aims […]

Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the nose and paranasal sinuses that is prevalent worldwide, affecting 10–12% of adults.1,2 It is phenotypically classified by the presence or absence of nasal polyps. Chronic rhinosinusitis with nasal polyposis (CRSwNP) is estimated to affect up to 4% of the population, and consists of multiple endotypes that […]

Watch a panel of experts discuss challenges in the diagnosis of CRSwNP and considerations for optimal management of the disease.

Dr Stella Lee (University of Pittsburgh, Pittsburgh, PA, US) spoke with touchRESPIRATORY around the SYNAPSE study, which investigated the efficacy and safety of mepolizumab in patients with chronic rhinosinusitis with nasal polyps (Clinical Trial Identifier: NCT03085797). The abstract ‘Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from […]